166 related articles for article (PubMed ID: 32535920)
1. Cost of decentralized CAR T-cell production in an academic nonprofit setting.
Ran T; Eichmüller SB; Schmidt P; Schlander M
Int J Cancer; 2020 Dec; 147(12):3438-3445. PubMed ID: 32535920
[TBL] [Abstract][Full Text] [Related]
2. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation.
Lam C; Meinert E; Yang A; Cui Z
Cytotherapy; 2021 May; 23(5):433-451. PubMed ID: 33674239
[TBL] [Abstract][Full Text] [Related]
3. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
[TBL] [Abstract][Full Text] [Related]
4. Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India.
Palani HK; Arunachalam AK; Yasar M; Venkatraman A; Kulkarni U; Lionel SA; Selvarajan S; Korula A; Abraham A; George B; Adair JE; Orentas R; Dropulic B; Mathews V
Bone Marrow Transplant; 2023 Feb; 58(2):160-167. PubMed ID: 36347999
[TBL] [Abstract][Full Text] [Related]
5. GMP CAR-T cell production.
Gee AP
Best Pract Res Clin Haematol; 2018 Jun; 31(2):126-134. PubMed ID: 29909913
[TBL] [Abstract][Full Text] [Related]
6. Comments on "Cost of decentralized CAR T cell production in an academic non-profit setting".
Schmitt M; Schmitt A; Thalheimer M; Dreger P; Müller-Tidow C
Int J Cancer; 2021 Jan; 148(2):514-515. PubMed ID: 32798335
[No Abstract] [Full Text] [Related]
7. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
8. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
[TBL] [Abstract][Full Text] [Related]
9. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
Gargett T; Truong N; Ebert LM; Yu W; Brown MP
Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
[TBL] [Abstract][Full Text] [Related]
10. Platforms for Clinical-Grade CAR-T Cell Expansion.
Mizukami A; Swiech K
Methods Mol Biol; 2020; 2086():139-150. PubMed ID: 31707673
[TBL] [Abstract][Full Text] [Related]
11. Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers.
Talarmin C; Kerob S; Cartier F; Madelaine I; Mukenyi S; Schwartz E; Boissel N; Baruchel A; Thieblemont C; Parquet N; Brignier A; Lesprit E; Desproges A; Magdelonnette L; Larghero J; Mebarki M
Cytotherapy; 2020 Dec; 22(12):792-801. PubMed ID: 32732084
[TBL] [Abstract][Full Text] [Related]
12. [Requirements for academic production of CAR-T cells in accordance with Good Pharmaceutical Practice (GMP). Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Deschamps M; Decot V; Giverne C; Pinturaud M; Vaissié A; Parquet N; Olivero S; Anne-Claire M; Bay JO; Yakoub-Agha I; Ferrand C
Bull Cancer; 2020 Jan; 107(1S):S85-S93. PubMed ID: 31547937
[TBL] [Abstract][Full Text] [Related]
13. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects.
Poorebrahim M; Sadeghi S; Fakhr E; Abazari MF; Poortahmasebi V; Kheirollahi A; Askari H; Rajabzadeh A; Rastegarpanah M; Linē A; Cid-Arregui A
Crit Rev Clin Lab Sci; 2019 Sep; 56(6):393-419. PubMed ID: 31314617
[TBL] [Abstract][Full Text] [Related]
14. A review of chimeric antigen receptor T-cells in lymphoma.
Anderson JK; Mehta A
Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
[No Abstract] [Full Text] [Related]
15. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
Cardle II; Cheng EL; Jensen MC; Pun SH
Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
[TBL] [Abstract][Full Text] [Related]
16. Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies.
Schwab RD; Bedoya DM; King TR; Levine BL; Posey AD
Methods Mol Biol; 2020; 2086():203-211. PubMed ID: 31707678
[TBL] [Abstract][Full Text] [Related]
17. Lentivirus Manufacturing Process for Primary T-Cell Biofactory Production.
Radhakrishnan H; Javitz HS; Bhatnagar P
Adv Biosyst; 2020 Jun; 4(6):e1900288. PubMed ID: 32390316
[TBL] [Abstract][Full Text] [Related]
18. Reply to: Comments on "Cost of decentralized CAR T cell production in an academic non-profit setting".
Ran T; Eichmüller SB; Schmidt P; Schlander M
Int J Cancer; 2021 Jan; 148(2):516-517. PubMed ID: 32798336
[No Abstract] [Full Text] [Related]
19. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
20. A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21.
Ptáčková P; Musil J; Štach M; Lesný P; Němečková Š; Král V; Fábry M; Otáhal P
Cytotherapy; 2018 Apr; 20(4):507-520. PubMed ID: 29475789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
